Results 81 to 90 of about 13,687 (277)

Ebolavirus Classification Based on Natural Vectors [PDF]

DNA and Cell Biology, 2015
According to the WHO, ebolaviruses have resulted in 8818 human deaths in West Africa as of January 2015. To better understand the evolutionary relationship of the ebolaviruses and infer virulence from the relationship, we applied the alignment-free natural vector method to classify the newest ebolaviruses.
Hui, Zheng, Changchuan, Yin, Tung, Hoang, Rong Lucy, He, Jie, Yang, Stephen S-T, Yau   +5 more
openaire   +2 more sources

Structural Basis of Pan-Ebolavirus Neutralization by an Antibody Targeting the Glycoprotein Fusion Loop

Cell Reports, 2018
Summary: Monoclonal antibodies (mAbs) with pan-ebolavirus cross-reactivity are highly desirable, but development of such mAbs is limited by a lack of a molecular understanding of cross-reactive epitopes.
Charles D. Murin, Jessica F. Bruhn, Zachary A. Bornholdt, Jeffrey Copps, Robyn Stanfield, Andrew B. Ward   +5 more
doaj   +1 more source

High prevalence of IgG antibodies to Ebola virus in the Efé pygmy population in the Watsa region, Democratic Republic of the Congo [PDF]

, 2016
Background Factors related to the natural transmission of Ebola virus (EBOV) to humans are still not well defined. Results of previous sero-prevalence studies suggest that circulation of EBOV in human population is common in sub- Saharan Africa.
Afounde, Afongenda, Borchert, Matthias, Kulidri, Amayo, Mulangu, Sabue, Muyembe-Tamfum, Jean-Jacques, Paweska, Janusz, Swanepoel, Robert, Tshomba, Antoine, Van der Stuyft, Patrick   +8 more
core   +1 more source

A Multivalent Pan-Ebolavirus Nanoparticle Vaccine Provides Protection in Rodents from Lethal Infection by Adapted Zaire and Sudan Viruses

bioRxiv
Both Zaire ebolavirus (EBOV) and Sudan ebolavirus (SUDV) are members of the family Filoviridae, first discovered in 1976 during outbreaks of hemorrhagic fever in northern Zaire and southern Sudan.
Natalie Brunette, Connor Weidle, Samuel P Wrenn, B. Fiala, Rashmi Ravichandran, Kenneth D. Carr, Samantha E Zak, Elizabeth E Zumbrun, R. Bakken, Michael Murphy, Sidney Chan, Rebecca Skotheim, Andrew J. Borst, L. Carter, Colin E Correnti, J. Dye, David Baker, Neil P. King, Lance Stewart   +18 more
semanticscholar   +1 more source

Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein [PDF]

Immunity, 2018
Ebolaviruses cause severe disease in humans, and identification of monoclonal antibodies (mAbs) that are effective against multiple ebolaviruses are important for therapeutics development. Here we describe a distinct class of broadly neutralizing human mAbs with protective capacity against three ebolaviruses infectious for humans: Ebola (EBOV), Sudan ...
Gilchuk, Pavlo, Kuzmina, Natalia, Ilinykh, Philipp A, Huang, Kai, Gunn, Bronwyn M, Bryan, Aubrey, Davidson, Edgar, Doranz, Benjamin J, Turner, Hannah L, Fusco, Marnie L, Bramble, Matthew S, Hoff, Nicole A, Binshtein, Elad, Kose, Nurgun, Flyak, Andrew I, Flinko, Robin, Orlandi, Chiara, Carnahan, Robert, Parrish, Erica H, Sevy, Alexander M, Bombardi, Robin G, Singh, Prashant K, Mukadi, Patrick, Muyembe-Tamfum, Jean Jacques, Ohi, Melanie D, Saphire, Erica Ollmann, Lewis, George K, Alter, Galit, Ward, Andrew B, Rimoin, Anne W, Bukreyev, Alexander, Crowe, James E   +31 more
openaire   +4 more sources

Immunogenicity and safety of Ebola virus vaccines in healthy adults: a systematic review and network meta-analysis

Human Vaccines & Immunotherapeutics, 2021
Clinical development of Ebola virus vaccines (EVV) was accelerated by the West African Ebola virus epidemic which remains the deadliest in history. To compare and rank the EVV according to their immunogenicity and safety.
Alhassane Diallo, Miguel Carlos-Bolumbu, Minerva Cervantes-Gonzalez, Veronika Wozniak, Mamadou Hassimiou Diallo, Boubacar Djelo Diallo, Alexandre Delamou, Florence Galtier   +7 more
doaj   +1 more source

Proteo-Genomic Analysis Identifies Two Major Sites of Vulnerability on Ebolavirus Glycoprotein for Neutralizing Antibodies in Convalescent Human Plasma

Frontiers in Immunology, 2021
Three clinically relevant ebolaviruses – Ebola (EBOV), Bundibugyo (BDBV), and Sudan (SUDV) viruses, are responsible for severe disease and occasional deadly outbreaks in Africa.
Pavlo Gilchuk, Adrian Guthals, Stefano R. Bonissone, Jared B. Shaw, Philipp A. Ilinykh, Philipp A. Ilinykh, Kai Huang, Kai Huang, Robin G. Bombardi, Jenny Liang, Ariadna Grinyo, Edgar Davidson, Elaine C. Chen, Bronwyn M. Gunn, Galit Alter, Erica Ollmann Saphire, Benjamin J. Doranz, Alexander Bukreyev, Alexander Bukreyev, Alexander Bukreyev, Larry Zeitlin, Natalie Castellana, James E. Crowe, James E. Crowe, James E. Crowe   +24 more
doaj   +1 more source

A recombinant vesicular stomatitis virus-based vaccine provides postexposure protection against Bundibugyo ebolavirus infection.

Journal of Infectious Diseases, 2023
BACKGROUND The filovirus Bundibugyo virus (BDBV) causes severe disease with a mortality rate of ∼20-51%. The only licensed filovirus vaccine in the U.S., Ervebo®, consists of a recombinant vesicular stomatitis virus (rVSV) vector that expresses Ebola ...
Courtney Woolsey, Jamie Strampe, Karla A. Fenton, K. Agans, Jasmine Martinez, V. Borisevich, Natalie S. Dobias, D. Deer, J. Geisbert, R. Cross, J. Connor, T. Geisbert   +11 more
semanticscholar   +1 more source

Ebolavirus vaccines for humans and apes [PDF]

Current Opinion in Virology, 2012
Because of high case fatality proportions, person-to-person transmission, and potential use in bioterrorism, the development of a vaccine against ebolavirus remains a top priority. Although no licensed vaccine or treatment against ebolavirus is currently available, progress in preclinical testing of countermeasures has been made.
Hugues, Fausther-Bovendo, Sabue, Mulangu, Nancy J, Sullivan   +2 more
openaire   +2 more sources

Strategic Preparedness of Broad‐Spectrum Antivirals for Rapid Response Towards Next Pandemics

Small Science, Volume 6, Issue 1, January 2026.
Nanoengineered broad‐spectrum antivirals (BSAs) represent a transformative approach to pandemic preparedness. Unlike virus‐specific drugs requiring separate development, BSAs act across multiple viral families through nanoengineering strategies that enhance solubility, bioavailability, and host‐targeted activity.
Sanoj Rejinold N, Geun‐woo Jin, Jin‐Ho Choy   +2 more
wiley   +1 more source